The company has developed three core technology platforms—antibody-drug conjugates (ADCs), biologics and small molecules—and its pipeline encompasses more than 30 innovative drug candidates, with over 10 in clinical development and several near regulatory submission. 

One of Kelun-Biotech’s flagship programmes is sacituzumab tirumotecan (sac-TMT), a TROP2-directed ADC undergoing global Phase III trials and approved by China’s NMPA for TROP2-positive non-small-cell lung cancer following EGFR-TKI therapy. 

In June 2025 the company placed 5.918 million H shares at HK$331.8 each, raising net proceeds of approximately US$250 million, planned for R&D, clinical trials, regulatory filings, manufacturing and commercialisation. 

With full-cycle in-house capabilities, a large and advancing pipeline and significant funding to support global development, Kelun-Biotech positions itself as a key Chinese innovator in the global oncology and biologics market.